GSK And Shionogi To Jointly Develop Super Bug Drug
This article was originally published in PharmAsia News
Executive Summary
Shionogi and GlaxoSmithKline agreed to collaborate to research, develop and market novel cephem antibiotics targeting Gram-negative bacteria